Webcast to be held on Monday, December 5e at 8:30 a.m. EST
CARMIEL, Israel, December 4, 2022 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant protein therapeutics produced by its owner ProCellEx® plant cell-based protein expression system, announced today that the company will host a key opinion leader (KOL) webinar on Fabry disease and PRX-102 (pegunigalsidase alfa) on Monday, December 5, 2022 at 8:30 a.m. Eastern Standard Time (EST).
The KOL Event webinar will feature Myrl D. HolidaPA-C, University of Iowa Stead Family Children’s Hospital, which will discuss the robust PRX-102 clinical program for the potential treatment of patients with Fabry disease. A live Q&A session will follow the formal presentations.
Myrl D. Holida is a medical assistant with 35 years of patient care experience, initially treating pediatric bone marrow transplant (BMT) patients with end-stage malignancies and patients with lysosomal storage disorders as part of a clinical test. Myrl’s experience includes many levels of research, from the cardiovascular animal laboratory to the clinical trial investigator for lysosomal storage disorders. He was involved in the original enzyme replacement trials for Fabry disease in the late 90s and early 2000s and was a principal investigator for the co-administration of oral chaperone therapy with agalsidase beta and migalastat, and for agalsidase alpha and velaglucerase “rescue therapy” during enzyme shortages beginning in 2009. Myrl brought initial Phase I PRX-102 trials of Protalix to his facility and recruited almost half of the United States patients with agalsidase beta in Protalix’s Phase III BRIGHT rollover clinical trial, which evaluated dosing every 4 weeks. His institution is a major Fabry Treatment Center, recently recognized as a Center of Excellence by the National Organization for Rare Disorders (NORD), thanks in part to his efforts over the years. He has treated patients with Adrenoleukodystrophy, Metachromatic Leukodystrophy, MPS I, MPS II, MPS III, MPS IV, MPS VI, Gaucher Disease, Lysosomal Acid Lipase Deficiency (LALD), Pompe disease and multiple hematological disorders. Myrl is also actively involved in a Fabry gene therapy trial and manages three generations of Fabry patients.
The webinar will be available via the following link: https://lifescievents.com/event/protalix-biotherapeutics-kol-event-on-fabry-disease-prx-102-pegunigalsidase-alfa/.
Please access the webinar at least 15 minutes before the KOL event to register, download and install any necessary audio software. The webinar will be available for replay for two weeks at the link above.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed by its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain US Food and Drug Administration (FDA) approval for a protein produced by a plant cell-based suspension expression system. Protalix’s unique expression system represents a novel method for developing recombinant proteins on an industrial scale.
ProCellEx’s first Protalix product, taliglucerase alfa, was approved by the FDA in May 2012 and subsequently by regulatory authorities in other countries. Protalix has licensed worldwide rights to develop and commercialize taliglucerase alfa to Pfizer Inc., excluding Brazilwhere Protalix retains all rights.
Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of recombinant human α-galactosidase-A protein for the treatment Fabry’s disease; alidornase alfa or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX-115, a recombinant PEGylated uricase expressed in plant cells for the treatment of severe gout; PRX-119, a long-acting plant cell-expressed DNase I for the treatment of NET-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici SpA, both in United States and outside United Statesfor the development and commercialization of pegunigalsidase alfa.
To the extent that statements contained in this press release are not strictly historical, all such statements are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms “expect” , “anticipate”, “believe”, “estimate”, “project”, “may”, “plan”, “will”, “would”, “should”, and “intend”, and other words or expressions of similar significance are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Such statements are based on our current beliefs and expectations about those future outcomes.Drug discovery and development involves a high degree of risk and the end results of a clinical trial may be e different from the preliminary results of the clinical trial. Factors that could cause material differences are described in our filings with the United States Securities and Exchange Commission. The statements contained in this press release speak only as of the date hereof and we undertake no obligation to update this information, except as required by law. The statements contained in this press release speak only as of the date hereof and we undertake no obligation to update this information, except as required by law.
Chuck PadalaGeneral director
SOURCEProtalix BioTherapeutics, Inc.